Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Tissue Regenix Group plc    TRX   GB00B5SGVL29

TISSUE REGENIX GROUP PLC

(TRX)
  Report
Delayed Quote. Delayed London Stock Exchange - 08/10 11:35:13 am
0.32 GBX   --.--%
02/04Tissue Regenix U.S. production resumes after cyber attack, shares jump
RE
2015TISSUE REGENIX : Preliminary Results for the Year Ended 31 January 2015
PR
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Business Summary
Logo Tissue Regenix Group plc
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Sales per Business
2019
GBP (in Million)%
Orthopaedics & Dental6.7251.6%
BioSurgery4.2332.5%
GBM-V2.0815.9%
Sales per region
20182019Delta
GBP (in Million)%GBP (in Million)%
United States9.4381.2%10.6881.9% +13.2%
Rest of World2.1918.8%2.3518.1% +7.73%
Managers
NameAgeSinceTitle
Gareth Hywel Jones51-CEO, COO & Executive Director
Jonathan Martin Glenn512020Non-Executive Chairman
Kirsten Lund--Secretary & Group Finance Director
Mike Izon--Director-Research & Development
Alan J. Miller552010Non-Executive Director
Randeep Singh Grewal522013Non-Executive Director
Shervanthi Homer-Vanniasinkam602016Non-Executive Director
Caitlin Pearson--Director-Corporate Communications
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 7,032,985,756 5,572,251,930 79.2% 0 0.0% 79.2%
Shareholders
NameEquities%
Lombard Odier Asset Management (Europe) Ltd. 1,057,187,187 15.0%
Premier Fund Managers Ltd. 764,414,600 10.9%
Richard Ian Griffiths 711,250,000 10.1%
Hargreaves Lansdown Stockbrokers Ltd. 423,107,000 6.02%
SpreadEx Ltd. 370,260,176 5.27%
Jupiter Asset Management Ltd. 350,876,717 4.99%
Diverse Income Trust PLC 303,701,093 4.32%
Jarvis Investment Management Ltd. 278,176,000 3.96%
Acacia Research Corporation 184,212,642 2.62%
IP Group Plc /Venture Capital/ 153,042,837 2.18%
Company contact information
Tissue Regenix Group Plc
Astley Lane Industrial Estate
Astley Way
Unit 1&2, Swillington
Leeds, Yorkshire LS26 8XT

Phone : +44.330.430.3052
Fax : +44.1904.380517
Web : http://tissueregenix.com
Sector Biotechnology & Medical Research - NEC
Connections : Tissue Regenix Group plc